tradingkey.logo

FDA Informs Sarepta That It Recommends That Sarepta Remove Its Pause And Resume Shipments Of Elevidys For Ambulatory Individuals With Duchenne Muscular Dystrophy

ReutersJul 28, 2025 9:11 PM

Sarepta Therapeutics Inc SRPT.O:

  • FDA INFORMS SAREPTA THAT IT RECOMMENDS THAT SAREPTA REMOVE ITS PAUSE AND RESUME SHIPMENTS OF ELEVIDYS FOR AMBULATORY INDIVIDUALS WITH DUCHENNE MUSCULAR DYSTROPHY

  • SAREPTA THERAPEUTICS INC - SHIPMENTS TO RESUME IMMINENTLY

  • SAREPTA THERAPEUTICS: CO AND FDA WILL CONTINUE DIALOGUE ON NEXT STEPS IN THE SAFETY LABELING PROCESS FOR ELEVIDYS

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI